4-P-PDOT是一种具有口服活性的、高选择性的褪黑激素MT2受体拮抗剂，它对MT2受体的选择性是MT1的300倍以上（Ki值分别为0.46nM和56nM）。
Cas No.:134865-74-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
4-P-PDOT is an orally active, highly selective melatonin MT2 receptor antagonist. 4-P-PDOT selectivity for the MT2 receptor is over 300 times greater than for MT1 (Ki values of 0.46nM and 56nM, respectively)[1-2]. 4-P-PDOT is primarily used in the field of neuroscience, particularly for research on sleep, circadian rhythms, and related cognitive functions[3-4].
In vitro, 4-P-PDOT (10μM) pretreatment of H9c2 cardiomyocytes for 4 hours, followed by anoxia/reoxygenation (A/R) injury, 4-P-PDOT significantly attenuated melatonin's protective effect on cell viability. 4-P-PDOT also exacerbated cell apoptosis, oxidative stress, and mitochondrial dysfunction[5]. 4-P-PDOT (10μM) was used to treat bone marrow mesenchymal stem cells from ovariectomized rats (after 2 hours of exposure to 100μM H₂O₂, treated for 72 hours). 4-P-PDOT significantly abolished melatonin's protective effect against oxidative stress-induced cellular senescence[6].
In vivo, 4-P-PDOT (5μg/μL; 1μL) was microinjected into the olfactory bulb of 6-OHDA Parkinson's disease model rats (single injection 7 days after injury). In the 6-OHDA-injured rats, 4-P-PDOT significantly induced antidepressant-like behaviors (reducing immobility time and increasing swimming time in the forced swim test)[7]. In a PTSD-like mouse model induced by 5 consecutive days of foot shock, 4-P-PDOT (2mM; 0.1mL/day) was intraperitoneally injected 15 minutes before melatonin (2mM) administration for two weeks. 4-P-PDOT slightly blocked melatonin's improvement of PTSD-like behaviors and mildly attenuated melatonin's restorative effects on serum GABA and cortisol levels[8].
References:
[1] Dubocovich ML. Melatonin receptors: are there multiple subtypes? Trends Pharmacol Sci. 1995 Feb;16(2):50-6.
[2] Shin EJ, Chung YH, Le HL, et al. Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int J Neuropsychopharmacol. 2014 Dec 30;18(6):pyu105.
[3] Dubocovich ML, Masana MI, Iacob S, et al. Melatonin receptor antagonists that differentiate between the human Mel1a and Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):365-75.
[4] Shin EJ, Chung YH, Le HL, et al. Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int J Neuropsychopharmacol. 2014 Dec 30;18(6):pyu105.
[5] Wu J, Yang Y, Gao Y, et al. Melatonin Attenuates Anoxia/Reoxygenation Injury by Inhibiting Excessive Mitophagy Through the MT2/SIRT3/FoxO3a Signaling Pathway in H9c2 Cells. Drug Des Devel Ther. 2020 May 25;14:2047-2060.
[6] Chen W, Lv N, Liu H, et al. Melatonin Improves the Resistance of Oxidative Stress-Induced Cellular Senescence in Osteoporotic Bone Marrow Mesenchymal Stem Cells. Oxid Med Cell Longev. 2022 Jan 18;2022:7420726.
[7] Noseda ACD, Rodrigues LS, Targa ADS, et al. MT2 melatonin receptors expressed in the olfactory bulb modulate depressive-like behavior and olfaction in the 6-OHDA model of Parkinson's disease. Eur J Pharmacol. 2021 Jan 15;891:173722.
[8] Xu Z, Li W, Sun Y, et al. Melatonin alleviates PTSD-like behaviors and restores serum GABA and cortisol levels in mice. Psychopharmacology (Berl). 2023 Feb;240(2):259-269.
4-P-PDOT是一种具有口服活性的、高选择性的褪黑激素MT2受体拮抗剂，它对MT2受体的选择性是MT1的300倍以上（Ki值分别为0.46nM和56nM）[1-2]。4-P-PDOT主要用于神经科学领域，特别是睡眠、 circadian 节律及相关认知功能的研究[3-4]。
在体外，4-P-PDOT（10μM）预处理H9c2心肌细胞4小时，随后进行缺氧/复氧（A/R）损伤，4-P-PDOT显著减弱了褪黑素对细胞存活率的提升作用，并加剧了细胞凋亡、氧化应激和线粒体功能障碍[5]。4-P-PDOT（10μM）体外处理卵巢切除大鼠骨髓间充质干细胞（在100μM H₂O₂暴露2小时后处理72小时），4-P-PDOT显著消除了melatonin对氧化应激诱导的细胞衰老的保护作用[6]。
在体内，4-P-PDOT（5μg/μL；1μL）微注射到嗅球处理6-OHDA帕金森病模型大鼠（在损伤后7天单次注射），4-P-PDOT在6-OHDA损伤大鼠中显著诱导抗抑郁样行为（减少强迫游泳测试中的不动时间，增加游泳时间）[7]。4-P-PDOT（2mM；0.1mL/day）在褪黑素（2mM）注射前15分钟腹腔注射处理创伤后应激障碍样小鼠（连续5天足底电击诱导）两周，4-P-PDOT轻微阻断了褪黑素对PTSD样行为的改善作用，并轻微减弱了褪黑素对血清GABA和皮质醇水平的恢复作用[8]。
| Cell experiment [1]: | |
Cell lines | H9c2 cells (rat cardiomyoblast cell line) |
Preparation Method | H9c2 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C, 5% CO₂. H9c2 cells were pretreated with 4-P-PDOT (10µM) for 4 hours prior to anoxia/reoxygenation (A/R) injury. |
Reaction Conditions | 10µM; 4h pretreatment. |
Applications | 4-P-PDOT significantly attenuated the cardioprotective effects of melatonin against A/R injury. 4-P-PDOT reversed melatonin-induced improvements in cell viability, reduction in apoptotic index, and decreases in intracellular Ca²⁺, LDH, and CK-MB levels. |
| Animal experiment [2]: | |
Animal models | Wistar rats (Parkinson's disease model induced by bilateral intranigral 6-OHDA lesion) |
Preparation Method | Rats were implanted with a guide cannula in the glomerular layer of the olfactory bulb (OB). Seven days post-surgery, rats received a single microinfusion of 4-P-PDOT (5μg/μL; 1μL) into the OB. Behavioral tests were conducted 30 minutes after drug administration. |
Dosage form | 5μg/μL of 1μL; OB microinfusion; Single administration. |
Applications | 4-P-PDOT administration produced differential effects depending on the animal's pathological state. In 6-OHDA-lesioned PD model rats, 4-P-PDOT significantly ameliorated depressive-like behaviors by reducing immobility frequency and increasing swimming frequency in the modified forced swimming test (MFST) compared to vehicle-treated PD rats. |
References: | |
| Cas No. | 134865-74-0 | SDF | |
| 别名 | AH 024 | ||
| 化学名 | N-((2R,4R)-4-phenyl-1,2,3,4-tetrahydronaphthalen-2-yl)propionamide | ||
| Canonical SMILES | O=C(CC)N[C@@H]1C[C@H](C2=CC=CC=C2)C3=CC=CC=C3C1 | ||
| 分子式 | C19H21NO | 分子量 | 279.38 |
| 溶解度 | 15 mg/ml in DMSO, 30 mg/ml in DMF, 5 mg/ml in Ethanol | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5794 mL | 17.8968 mL | 35.7935 mL |
| 5 mM | 715.9 μL | 3.5794 mL | 7.1587 mL |
| 10 mM | 357.9 μL | 1.7897 mL | 3.5794 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet